Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topotecan and Paclitaxel in Relapsed Small Cell Lung Cancer
NCT00003281Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Apr 1998
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of topotecan and paclitaxel in small cell lung cancer (SCLC), sponsored by Cancer and Leukemia Group B. Primary endpoints: Objective Response Rate up to 5 years and Toxicity up to 5 years. Started Apr 1998; status: completed.
02
Drugs
topotecanpaclitaxel
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00003281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003281.